Reported a robust objective response rate of 75.5% from the Phase 1 study of NX-5948 in patients with relapsed/refractory CLL/SLL at the 66th American Society of Hematology Annual Meeting Received ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback